Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-24-118265
Filing Date
2024-04-26
Accepted
2024-04-26 16:49:02
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A d778708ddefa14a.htm DEFA14A 22207
2 GRAPHIC g778708dsp2a.jpg GRAPHIC 108594
3 GRAPHIC g778708dsp2b.jpg GRAPHIC 128063
4 GRAPHIC g778708dsp3a.jpg GRAPHIC 1608
  Complete submission text file 0001193125-24-118265.txt   351876
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33038 | Film No.: 24884741
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)